Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to school age))** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Motor outcome in infancy (Bayley, Griffiths Locomotor) · preterm infants
1 finding from 1 review
Motor outcome at school age (Griffiths Locomotor, MABC) · preterm infants
2 findings from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with surfactant administration via endotracheal tube (ETT) with the… (low certainty).
1 finding from 1 review
Pulmonary air leak · preterm infants with or at risk of respiratory distress syndrome
It is very uncertain whether surfactant administration via laryngeal mask airway (S‐LMA) changes pulmonary air leak, any (during first hospitalisation) Anytime to… compared with surfactant administration via endotracheal tube (ETT) with… (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraventricular haemorrhage, Papile grade 3/4 · preterm infants with or at risk of respiratory distress syndrome
It is very uncertain whether surfactant administration via laryngeal mask airway (S‐LMA) changes intraventricular haemorrhage grade III and IV Anytime to discharge compared with surfactant administration via endotracheal tube (ETT) with… (very low certainty).
1 finding from 1 review